BillionToOne (BLLN) Reports Q1 Earnings: What Key Metrics Have to Say

BillionToOne (BLLN) reported $108.39 million in revenue for the quarter ended March 2026, representing no change year over year. EPS of $0.34 for the same period compares to $0 a year ago.The reported revenue represents a surprise of +13.13% over the Zacks Consensus Estimate of $95.81 million. With the consensus EPS estimate being $0.01, the EPS surprise was +3300%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how BillionToOne performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Total tests delivered: 188,000 versus the two-analyst average estimate of 183,188.Overall ASP: $571.00 compared to the $526.07 average estimate based on two analysts.Revenue- Clinical Trial Support and Other Services: $1.1 million versus the three-analyst average estimate of $1.21 million.Revenue- Prenatal: $96.5 million versus $85.76 million estimated by three analysts on average.Revenue- Oncology: $10.7 million compared to the $9.89 million average estimate based on three analysts.View all Key Company Metrics for BillionToOne here>>>Shares of BillionToOne have returned -9.7% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks